[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628966":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":95,"collaborators":97,"id":112,"slug":113,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":25,"eligibilityCriteria":117,"healthyVolunteers":114,"sex":118,"minAge":119,"maxAge":25,"enrollmentInfo":120,"targetDuration":25,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":33,"whyStopped":25,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Menzies School of Health Research","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants with G6PD intermediate status receive another active regimen appropriate for intermedia","ACTIVE_COMPARATOR","G6PD activity 30-\\\u003C70%",[13],"Drug: Patients with G6PD enzyme activities between 30 and \u003C70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg\u002Fkg\u002Fday for 7 days",{"label":15,"type":10,"description":16,"interventionNames":17},"Participants withG6PD deficient status receive a specific treatment regimen appropriate for deficie","G6PD activity ≤30%",[18],"Drug: Patients with G6PD enzyme activities \u003C30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg\u002Fkg dose).",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Patients with G6PD enzyme activities between 30 and \u003C70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg\u002Fkg\u002Fday for 7 days","Primaquine 1mg\u002Fkg\u002Fday for 7 days",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Patients with G6PD enzyme activities \u003C30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg\u002Fkg dose).","8 weekly Primaquine (0.75mg\u002Fkg dose).",[15],[31,49,65,81],{"facility":32,"status":33,"city":34,"state":25,"zip":25,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Dr Marcus Lacerda","RECRUITING","Manaus","Brazil","BR",{"type":38,"coordinates":39},"Point",[40,41],-60.025,-3.10194,{"lat":41,"lon":40},[44],{"name":45,"role":46,"phone":47,"phoneExt":25,"email":48},"Aretha Omena","CONTACT","+55984208810","aretha.omena@gmail.com",{"facility":50,"status":51,"city":52,"state":25,"zip":25,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Arba Minch General Hospital","NOT_YET_RECRUITING","Arba Minch","Ethiopia","ET",{"type":38,"coordinates":56},[57,58],37.55,6.03333,{"lat":58,"lon":57},[61],{"name":62,"role":46,"phone":63,"phoneExt":25,"email":64},"Tamiru Shibiru Degaga, MD","+251911704767","tamiru.shibiru@menzies.edu.au",{"facility":66,"status":33,"city":67,"state":68,"zip":25,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"Dr Moses Laman and Dr Brioni Moore","Alexishafen","Madang Province","Papua New Guinea","PG",{"type":38,"coordinates":72},[73,74],145.80288,-5.09074,{"lat":74,"lon":73},[77],{"name":78,"role":46,"phone":79,"phoneExt":25,"email":80},"Dr Paula Tesine Doctor, Medical Doctor","+67570755875","paula.tesine@pngimr.org.pg",{"facility":82,"status":33,"city":83,"state":84,"zip":25,"country":69,"countryCode":70,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Papua New Guinea Institute of Medical Research","Port Moresby","Magang",{"type":38,"coordinates":86},[87,88],147.15089,-9.47723,{"lat":88,"lon":87},[91],{"name":92,"role":46,"phone":93,"phoneExt":25,"email":94},"DR Moses Laman","+6754340208","moses.laman@pngimr.org.pg",{"type":96,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[98,100,102,104,106,108,110],{"name":99,"class":6},"Curtin University",{"name":101,"class":6},"University of Melbourne",{"name":103,"class":6},"Arba Minch University",{"name":82,"class":105},"OTHER_GOV",{"name":107,"class":6},"Mahidol Oxford Tropical Medicine Research Unit",{"name":109,"class":6},"Oxford University Clinical Research Unit, Vietnam",{"name":111,"class":6},"Indonesia University","100628966","phase-4-primaquine-for-vivax-malaria-in-g6pd-intermediate-and-deficient-cases-100628966",false,"NCT07468513","Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.","Inclusion Criteria:\n\n* • P. vivax peripheral parasitaemia (mono-infection)\n\n  * G6PD intermediate or deficient status (G6PD activity 30-\\\u003C70% or ≤30% of the adjusted male median as determined by the Standard G6PD (SDBioline, ROK))\n  * Fever (temperature ≥37.5⁰C) or history of fever in the preceding 48 hours\n  * Age ≥18 years\n  * Haemoglobin at presentation ≥8g\u002Fdl\n  * Written informed consent\n  * Living in the study area and willing to be followed for six months.\n\nExclusion Criteria:\n\n* • Danger signs or symptoms of severe malaria\n\n  * Pregnant or lactating females\n  * Regular use of drugs with haemolytic potential\n  * Known hypersensitivity to any of the study drugs.","ALL","18 Years",{"count":121,"type":122},100,"ESTIMATED","INTERVENTIONAL",[125],"PHASE4","A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg\u002Fkg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of weekly primaquine among patients who are g6Pd deficient (\\\u003C30% activity)",[128,129],"Vivax Malaria","G6PD Deficiency",[131,132],"Primaquine in G6PD deficiency","Vivax malaria in G6PD deficient patients","2026-03-09",{"date":135,"type":136},"2026-03-12","ACTUAL",{"date":138,"type":136},"2024-05-17",{"date":140,"type":122},"2028-12-31",{"name":5,"class":6},4]